Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.

Oxymorphone: a review. Support Care Cancer (2005) 0.83

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metab Dispos (2016) 0.79

Update on prescription extended-release opioids and appropriate patient selection. J Multidiscip Healthc (2013) 0.77

Review of oral oxymorphone in the management of pain. Ther Clin Risk Manag (2008) 0.75

Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. Arch Drug Inf (2008) 0.75

Dose Proportionality of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. Arch Drug Inf (2008) 0.75

Oxymorphone Extended-Release Tablets (Opana ER) For the Management of Chronic Pain: A Practical Review for Pharmacists. P T (2010) 0.75

Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. Arch Drug Inf (2008) 0.75

The dimensions of pain quality: factor analysis of the Pain Quality Assessment Scale. Clin J Pain (2008) 1.61

Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain (2006) 1.21

The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome. J Pain (2006) 1.17

Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain (2006) 1.14

A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin (2007) 1.03

Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain (2012) 0.99

Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin (2004) 0.95

A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther (2006) 0.95

Frequency of chronic pain descriptors: implications for assessment of pain quality. Eur J Pain (2011) 0.93

Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med (2002) 0.91

Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin (2004) 0.91

Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin (2004) 0.91

Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. J Pain (2011) 0.91

Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning? J Pain (2006) 0.90

Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults. Clin Ther (2008) 0.90

Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med (2005) 0.90

Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy (2004) 0.89

The words patients use to describe chronic pain: implications for measuring pain quality. Pain (2013) 0.87

Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain (2005) 0.87

A comparison of the lidocaine patch 5% vs naproxen 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group study. MedGenMed (2006) 0.87

Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin (2004) 0.87

Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis (2010) 0.85

More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med (2003) 0.85

Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial. Clin Ther (2007) 0.84

Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther (2005) 0.84

The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg (2004) 0.82

Cognitive testing and revision of the pain quality assessment scale. Clin J Pain (2013) 0.82

Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D (2005) 0.82

Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. J Opioid Manag (2010) 0.81

Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J Pediatr Gastroenterol Nutr (2009) 0.81

Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain. Pain Med (2008) 0.80

The relationship of changes in pain quality to pain interference and sleep quality. J Pain (2010) 0.80

Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer (2004) 0.80

The assessment of pain quality: an item response theory analysis. J Pain (2010) 0.79

Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial. Arch Phys Med Rehabil (2005) 0.79

Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia. Blood (2002) 0.78

The pain quality response profile of oxymorphone extended release in the treatment of low back pain. Clin J Pain (2009) 0.78

The pain quality response profile of pregabalin in the treatment of neuropathic pain. Clin J Pain (2012) 0.77

Regarding CYP450 2D6 poor metabolizers. Pain Pract (2008) 0.77

Comment: Oral oxymorphone for pain management. Ann Pharmacother (2007) 0.75

Effectiveness of lidocaine patch 5% in patients with or without allodynia. CNS Spectr (2006) 0.75

The pain quality response profile of a corticosteroid injections and heated lidocaine/tetracaine patch in the treatment of shoulder impingement syndrome. Clin J Pain (2015) 0.75

Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers. J Clin Pharmacol (2002) 0.75

The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. Am J Cardiovasc Drugs (2003) 0.75